-

Aphios Awarded NIH SBIR Grant For Development of Anti-CCR5 Nanoparticles to Treat Alzheimer’s Disease

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios announced today that it was awarded an NIH SBIR grant from the National Institute on Aging (NIA) to develop anti-CCR5 nanoparticles to treat Alzheimer’s disease.

Alzheimer's disease and dementia are debilitating diseases affecting over 6.7 million people in the United States and over 55 million people worldwide. Alzheimer's disease has been characterized by multiple factors, including but not limited to amyloid plaque formation, tau protein entanglement, enzyme degradation and inflammation. Inflammation in the brain is associated with the CCR5 gene that increases with age. CCR5 has been correlated with impairments in memory consolidation in aged mice, which was reversed with a CCR5 knockout drug that inhibits this receptor.

According to Dr. Trevor P. Castor, Principal Investigator, “We are utilizing targeted nanoparticles manufactured by our proprietary PNS (polymer nanoparticles) technology to transport the anti- CCR5 antagonist across the blood brain barrier (BBB) to knock down the CCR5 gene, control inflammation, and manage dementia and Alzheimer’s disease.” Additionally, he continues, “Our nanotechnology platform will be able to co-transport our anti-CCR5 antagonist with other therapeutics such as anti-amyloid antibodies with different and potentially synergistic mechanisms of actions into the Alzheimer's disease brain.”

About Aphios Corporation:

Aphios Corporation is a clinical stage biotechnology company developing enabling technology platforms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety of biologics. Based on these platforms, we are developing enhanced therapeutics to prevent disease, maintain health/improve quality-of-life and treat chronic diseases including cancers/supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19, and CNS disorders such as Alzheimer’s disease in an environmentally sustainable manner.

Research reported in this press release is supported by the National Institute on Aging (NIA) of the National Institutes of Health (NIH) under Award Number R43AG085863. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contacts

Trevor P. Castor, Ph.D., CEO
(001) 781-858-7520
tcastor@aphios.com

Aphios Corporation


Release Versions

Contacts

Trevor P. Castor, Ph.D., CEO
(001) 781-858-7520
tcastor@aphios.com

Social Media Profiles
More News From Aphios Corporation

Aphios Receives U.S. Patent Allowance for Groundbreaking Room Temperature-Stable, Single-Shot mRNA COVID-19 Vaccine

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios has received a patent allowance for a single-dose, room temp-stable mRNA COVID-19 vaccine. No cold chain. No PEG. Just sustained protection....

Aphios Granted US Patent for Thermal Conversion of CBDA and Other Carboxylic Acid Cannabinoids

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios announced today that it was granted US Patent No. 11,981,174 for the thermal conversion of CBDA to CBD and other carboxylic acid cannabinoids to cannabinoids. The patent was granted for a process to improve the manufacturing of pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA. The major cannabinoids in marijuana (Cannabis) originate from cannabigerolic acid (CBGA) and are converted b...

Aphios Corporation Granted Japanese Patent for Novel Compositions to Treat Folic Acid Deficiency and Morning Sickness

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios Corporation announced today that it has been granted Japanese Patent No. 7,520,838 for novel compositions to treat folic acid deficiency and morning sickness. The dosage forms have an effective amount of a folic acid, gingerols and shogaols to suppress nausea, relieve gastric distress and promote hematopoiesis. Pregnancy related nausea and vomiting (PRNV) is the most common medical condition during pregnancy. PRNV affects up to 70% of women during t...
Back to Newsroom